Dear editor,Patients with clear-cell renal cell carcinoma(ccRCC)potentially have a high recurrence rate of more than 40%[1].Patients receive radical or partial nephrectomy,sometimes assisted by targeted therapies or/a...Dear editor,Patients with clear-cell renal cell carcinoma(ccRCC)potentially have a high recurrence rate of more than 40%[1].Patients receive radical or partial nephrectomy,sometimes assisted by targeted therapies or/and immune checkpoint inhibitors(ICIs),to improve overall survival(OS)[2].Large-cohort studies and large-scale human tissue sequencing have provided a series of molecular subtyping methods for precision medicine-based ccRCC risk stratification and therapeutic regimens,such as ClearCode34,the prognostic risk predictor[3],and seven subsets for ICI and angiogenesis blockade outcomes[4].However,these subtyping results are all based on human genomes without including the host microbiota,which may be non-negligible genome components.展开更多
基金sponsored by the National Natural Science Foundation of China(Nos.81974391,82072806,and 82173265)the National Natural Science Foundation of China for Youths(No.8200100057)+6 种基金Program of Shanghai Academic/Technology Research Leader(No.19XD1405100)Clinical Research Plan of SHDC(No.SHDC2020CR4025)Shanghai“Rising Stars of Medical Talent”Youth Development Program:Youth Medical Talents-Specialist Program(Xiuwu Pan)Shanghai Municipal Commission of Health and Family Planning(No.20204Y0042)Technology Project of Jiading District Health System(No.2019-QN-03)Natural Science Foundation of Shanghai(No.20ZR1470500)Hospital Funded Clinical Research,Xinhua Hospital,Shanghai Jiao Tong University School of Medicine(No.21XHDB06).
文摘Dear editor,Patients with clear-cell renal cell carcinoma(ccRCC)potentially have a high recurrence rate of more than 40%[1].Patients receive radical or partial nephrectomy,sometimes assisted by targeted therapies or/and immune checkpoint inhibitors(ICIs),to improve overall survival(OS)[2].Large-cohort studies and large-scale human tissue sequencing have provided a series of molecular subtyping methods for precision medicine-based ccRCC risk stratification and therapeutic regimens,such as ClearCode34,the prognostic risk predictor[3],and seven subsets for ICI and angiogenesis blockade outcomes[4].However,these subtyping results are all based on human genomes without including the host microbiota,which may be non-negligible genome components.
